Celcuity Bolsters ASCO‑highlighted Breast Cancer Drug Case
Celcuity strengthens case for ASCO-spotlighted breast cancer drug https://t.co/HdekunGXsu by @Lilah_Alvarado $CELC + 18% $NVS $AZN $RHHBY
Wall Street Sees BMY Lift, BIIB Rise, REGN Uncertainty
Latest snapshot of Wall Street's take on a trio of earnings reports, from @ByJonGardner and @realJacobBell Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook https://t.co/PnGb0o93WL $BIIB $BMY $REGN
UniQure Pursues UK Approval for Huntington’s Gene Therapy
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy https://t.co/plxdEw43FD by @Lilah_Alvarado $QURE + 22% #GeneTherapy
Teva Spends $700M on Tourette Drug, Shares Jump 11%
Teva nabs experimental Tourette drug in $700M Emalex buyout https://t.co/z1byYRgYul by @realJacobBell $TEVA + 11%
FDA Pilots Real-Time Trials as AbbVie Eyes KRAS Biotech
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech https://t.co/diuieVTJ3g $ABBV $LLY $GSK $IONS $PFE #biotech
Chiesi Acquires KalVista for $1.9B Rare Disease Drug
Chiesi to buy KalVista in $1.9B deal for rare disease drug https://t.co/VR9hDYGLGJ by Kristin Jensen $KALV $PHVS $NTLA $BCRX $IONS
Pfizer Secures Patent Extension for Leading Rare‑Disease Drug
Pfizer deals extend patent life for a top-selling rare disease drug https://t.co/uXXbtLaIOL $PFE $BBIO $ALNY $IONS
FDA Accuses Amgen of Data Manipulation; Erasca Falls
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results https://t.co/UbftjXwEwa $AMGN $ERAS - 53% $RCKT $JANX
Coultreon Secures $125M to Test Former Galapagos Immune Drug
Coultreon banks $125M to support testing of former Galapagos immune drug https://t.co/PUsEu2i7Vv by @Lilah_Alvarado $GLPG #biotech #startups
Biotech Firms Rise to Top, Sector More Investable Now
A group of biotechs have recently ascended into the sector’s upper ranks, suggesting the sector may be more ‘investable’ now than it once was, @gwendolynawu reports: https://t.co/WRl1jpnA9G $BBIO $ARGX $MDGL $INSM #biotech
Eli Lilly Acquires Ajax to Strengthen JAK Pipeline
Lilly to buy startup Ajax in bid for a better JAK drug https://t.co/RMQQZ4mRFG $INCY $BMY $LLY $TAK #biotech #startups
Lilly Slides as FDA Plans Psychedelic Voucher Program
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics https://t.co/kWvYtFeif0 $LLY - 4% $NVO + 6% $REGN $AMGN $BBOT #biotech
Roche Bets on Cancer and Obesity Drugs Amid Biosimilar Pressure
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs https://t.co/IIt0INA9sI @ByJonGardner $RHHBY
Sanofi Reports Strong Sales Amid Growing R&D Pressure
Sanofi posts upbeat sales as R&D pressure builds https://t.co/4WUccjXY5D by Kristin Jensen $SNY + 2% $REGN
Moderna Launches mRNA Bird Flu Trial After Funding Loss
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial https://t.co/cKyC9jfWAj by Kristin Jensen $MRNA
Merck Expands AI Push; Roche Reports MS Drug Data
Merck adds to pharma’s AI push; Roche details MS drug results https://t.co/VmpWyLhP9A $MRK $RHHBY $TGTX $RCUS $GILD #biotech
BioAge's Inflammation Drug Shows Best‑in‑class Promise
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug https://t.co/D2owlYxCRa by Kristin Jensen $BIOA $LLY $NMRA
Trump Order Boosts Psychedelic Biotech Stocks
Trump executive order lifts psychedelics biotechs https://t.co/3H00cxuF4A by @realJacobBell $GHRS $HRELP $DFTX $ENVB $COMP $ATAI #biotech
Serif Targets Revolutionary Genetic Medicine Platform
Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine https://t.co/kvmbF3xYKu by @gwendolynawu #biotech #startups @FlagshipPioneer
Nektar Jumps as Alopecia Drug Shows Promise
Nektar surges again as alopecia drug shows new promise in extension study https://t.co/UV0ccY4HiR @ByJonGardner $NKTR + 25% $LLY
AACR 2026 Unveils Merck Breakthrough and Lung Cancer Hope
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle https://t.co/u2iwCd3DKv #AACR26 $RVMD $MRK $NUVL $NUVB
UCB to Acquire Neurona for $1.2B, Targeting Seizure Cell Therapy
UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B https://t.co/LxI1Omodan by @realJacobBell $UCB
Lilly's Obesity Pill Gains Momentum; OpenAI Launches Discovery Tool
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool https://t.co/upwygATKAv $LLY $GILD $JANX #biotech
Kailera Raises $625M in Major Biotech IPO
From @gwendolynawu: Kailera nets $625M in one of biotech’s biggest-ever IPOs https://t.co/SJWx2QBmSn $KLRA #biotech $LLY $NVO $GPCR $VKTX #IPO
Replimune Downsizes While MeiraGTx Regains Eye Therapy
Replimune cuts staff; MeiraGTx reacquires eye gene therapy https://t.co/LqGPyNzRA3 $REPL $MGTX $JNJ $BIIB $RVMD $APLS
Novo Partners OpenAI as Ideaya's Eye Data Disappoints
Novo teams with OpenAI; Ideaya gets muted response to eye drug data https://t.co/U6sDZlMxyQ $NVO $IDYA $REGN $GSK
Off‑the‑Shelf CAR‑T Shows Promise Delaying Lymphoma Relapse
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma https://t.co/UrSNYpQFqB by @gwendolynawu $ALLO + 25%
Pancreatic Cancer Drug Nearly Doubles Survival in Trial
Revolution pancreatic cancer drug nearly doubles survival in key trial https://t.co/SvJicU0LIz @ByJonGardner $RVMD + 38%
Avalyn Targets Hard-to-Treat Lung Disease, Prepares IPO
Chasing a tough-to-treat lung disease, Avalyn plans an IPO https://t.co/743svTKTS4 by @gwendolynawu #IPO $AVLN $BMY $ABBV
Eli Lilly's GLP-1 Pill Ignites Rivalry with Novo
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk https://t.co/zM6udFvuNE by Kristin Jensen $LLY $NVO #obesity
Novo Undercuts Lilly with Pricier Wegovy; Insmed Braces for Flop
Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure https://t.co/jN9GuuOf4s $NVO $LLY $INSM $VRTX $BIIB
Gilead's $3.1B Deal Expands ADC Portfolio
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis https://t.co/xEMXvDq2LL by @gwendolynawu $GILD #biotech
Study Shows Subcutaneous Tepezza Matches Infused Version
Under-the-skin Tepezza comparable to infused version in key study, Amgen says https://t.co/rOQqbRmEpL $AMGN $VRDN - 25%
Key FDA Decisions Shaping Biotech Q2 2026
New: 5 FDA decisions to watch in the second quarter of 2026 https://t.co/AVvu8i9kgh $REPL $LLY $AXSM $PFE $ARVN $IONS $ARWR #biotech
AstraZeneca's Lung Drug Scores Unexpected COPD Trial Win
AstraZeneca lung drug gets ‘surprise’ win in COPD trials https://t.co/QuRlOQtzdT @ByJonGardner $AZN $RGN $SNY $RHHBY
Novartis Acquires Excellergy to Secure Xolair Successor
Novartis targets Xolair successor in buyout of startup Excellergy https://t.co/eGYQ2AxTd5 by @gwendolynawu $NVS $RHHBY #startups #biotech
Obesity Drug News Sinks Wave, Lifts Kodiak
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends https://t.co/20H9OXVtIB $WVE - 54% $KOD + 58%
FDA Approval Propels Denali, Boosts Rare Disease Biotech
FDA clears Denali drug in ‘clear step’ for rare disease biotechs https://t.co/x9yL4nyPaj by Kristin Jensen $DNLI #biotech
Former Acorda CEO Joins Parkinson’s Cell Therapy Startup
How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup https://t.co/93JYvJGM9I by @realJacobBell #biotech #startups
FDA Review and Study Data Lift Insmed Stock
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares https://t.co/BCRJAUwGIJ $INSM + 7% $SRPT $SNY $GSK #biotech
RBC Flags Revolution, Xenon, Arrowhead as Top Biotech Takeover Targets
RBC: Revolution, Xenon, Arrowhead among top #biotech takeover targets https://t.co/h1toH9szrU by @realJacobBell $ARWR $XENE $RVMD $DYNE
Excalipoint Secures $69M for Next‑Gen T‑Cell Engagers
Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers https://t.co/809RqRWJNL by @gwendolynawu #biotech #startups
Bicycle Cuts 30% Staff, Abandons Padcev Challenger
Bicycle to lay off 30% of staff, pivot away from Padcev challenger https://t.co/m3JFu2mwoB @ByJonGardner $BCYC $PFE $MRK
Pfizer's Ibrance Successor Advances with Fresh Study Data
Pfizer’s Ibrance successor moves forward with new study data https://t.co/ozXAZYmc3M by Kristin Jensen $PFE $LLY $NVS $RHHBY $ONC
R1 Secures $78M to Advance Kidney Drug Development
R1 starts up with $78M, aiming for a better kidney drug https://t.co/PQQjX47ODM by @gwendolynawu #biotecjh #startups
CytomX Jumps 66% on Promising Colorectal ADC Data
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer https://t.co/PxQMISvyri by @Lilah_Alvarado $CTMX + 66%
Structure's GLP-1 Pill Shows Best-in-Class Obesity Results
Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial https://t.co/j0fzAg6GRV @ByJonGardner $GPCR $LLY $NVO $AZN $MRK #obesity
Sarepta Tests Elevidys Safety, Sana
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy https://t.co/hkixuANCCV $SRPT $SANA $INO $BAYRY #biotech
China Biotech Receives FDA Approval for First Cell Therapy Trial
With FDA go ahead, a China #biotech notches a first in cell therapy testing https://t.co/QorwJmou8w by @realJacobBell $XENE $BHVN
Biotech Layoffs Hit Evotec, Vistagen; Immutep Shares Plunge
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure https://t.co/OikmCdJ6sg $EVO $VTGN $IMMP - 81% $RARE $ATRA